CSL Hong Kong Aleviate Human Coagulation Factor VIII 500IU/von Willebrand factor 1000IU complex, Powder for injection (50 IU/mL FVIII)

Pays: Australie

Langue: anglais

Source: Department of Health (Therapeutic Goods Administration)

Ingrédients actifs:

Von willebrand factor, Quantity: 1000 IU; Factor VIII, Quantity: 500 IU

Disponible depuis:

CSL Behring Australia Pty Ltd

DCI (Dénomination commune internationale):

Factor VIII,Von willebrand factor

forme pharmaceutique:

Injection, solution

Composition:

Excipient Ingredients: water for injections

Mode d'administration:

Intravenous

indications thérapeutiques:

Aleviate is indicated for: ? the treatment of bleeding episodes including surgical bleeding in patients with von Willebrand disease when desmopressin (DDAVP) treatment is ineffective or contraindicated. ? the treatment and prophylaxis of bleeding associated with factor FVIII deficiency due to haemophilia A.

Descriptif du produit:

Visual Identification: Clear, colourless solution; Container Life Time: 3 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Statut de autorisation:

Listed (Export Only)

Date de l'autorisation:

2004-06-17